What about Truvada-resistant strains of HIV?

Encountering an HIV-positive individual with a Truvada-resistant strain is very rare [note 1]. The medication we call Truvada contains two different drugs: tenofovir (TDF) and emtricitabine (FTC). To break through the protection of PrEP, a strain of HIV would have to be resistant to both these drugs. In addition to both these resistances a person would have to have detectable viral load, in order to pass this strain on to someone else. HIV that is resistant to Truvada also has a lower capacity to replicate, spread, and cause disease. For all these factors to fall into place is possible, but exceedingly rare. In studies of two different cities, only about 0.001% of HIV circulating in the population met these criteria [2], [3].

Can PrEP protect against such rare drug-resistant strains of HIV? The short answer seems to be “not always.” There are now two documented cases (among many tens of thousands of PrEP users) where a patient, not in a research study, contracted a multi-drug-resistant strain of HIV despite adhering to daily use of PrEP [4]. There were no such cases in any of research studies on PrEP, and there are no other documented cases in clinical practice. Cases like this are likely to remain rare.

To quote Bob Grant, who led the iPrEX study (the first study that demonstrated that PrEP works): “The prevalence of this kind of virus among recently infected persons is less than 1%. Maybe much less. If PrEP is not fully effective against viruses that are HIGHLY resistant to both drugs in FTC/TDF PrEP, the efficacy of PrEP when taken may decrease from 99% to 98%. Or from 99.9% to 98.9%. Or from 100% to 99%. The decimal points are not certain.” [5]

No prevention method is 100% effective. Daily PrEP, however, provides a very high level of protection from HIV. It has been shown to reduce the risk of contracting HIV by 92-99%, depending on the study [6]. Verifying your HIV-negative status before starting PrEP, taking the medication as directed, and completing your quarterly medical visits on time are still the keys to using PrEP in the safest and most responsible way possible.

Notes & Sources

  1. 3 Drug PrEP?, Robert M. Grant, MD and Low prevalence of transmitted K65R and other tenofovir resistance mutations across different HIV-1 subtypes: implications for pre-exposure prophylaxis, Chan, P.A. et. al.
  2. In Vancouver, Canada, the proportion of patients with a plasma sample containing circulating virus that was resistant to FTC, TDF, or both was 1.7%, 0.004%, and 0.001%, respectively, in 2014–2015.
  3. In King County (Seattle), USA, of 2,323 new HIV diagnoses between 2008 and 2017, only 3 had primary FTC/TDF resistance. All of these became virally undetectable with treatment, meaning these individuals are incapable of transmitting HIV to a sex partner, with or without PrEP. https://www.aidsmap.com/page/3245143/
  4. For more on these two cases, see HIV Infection Despite PrEP: 6 Things You Need to Know and Despite Second Case of HIV, PrEP Still 'Most Effective Tool for HIV Prevention.
  5. Dr. Robert Grant weighs in after the first case of failed PrEP: What does it mean?, BETA Blog, 25 February 2016.
  6. PreP Basics, US Centers for Disease Control and PrEP: PK Modeling of Daily TDF/FTC (Truvada) Provides Close to 100% Protection Against HIV Infection and How Much 'PrEP-resistant' HIV is Out There?
Revised 9 December 2018 — Give feedback on this page